– JBI-778, abrain penetrant PRMT5 inhibitor demonstrated significant tumor growth inhibition in glioblastoma in addition to its activity against a number of other cancers–
– JBI-1527, a potent, selective oral inhibitor of PD-L1 exhibited T-cell restorationand immune-mediated tumor growth suppression –
– Data support the further development of PRMT5 inhibitor JBI-778 and PD-L1 inhibitor JBI-1527 for the treatment of unmet need in oncology
Jubilant Therapeutics Inc. announced that preclinical data fromtwo programs evaluating the company’s PRMT5 inhibitor and PD-L1 inhibitor as anti-cancer agents, will be presented today in a poster session at the American Association for Cancer Research (AACR) 2021 Annual Meeting taking place virtually from April 10-15, 2021.
“We are excited to announce theseimportant data from our PRMT5 and our PD-L1programs that show efficacy and tolerability in preclinical models,” said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics Inc. “Our oral PRMT5 inhibitor has good plasma and sustained brain exposure which results in strong target inhibition, tumor growth delay and survival advantage in both xenografts and orthotopic brain models. Our oral anti-PDL1 immunotherapeutics,with a shorter half-life,are an attractive alternative to current intravenous antibody therapies especially in the maintenance settingswith potential to limitimmune-mediated toxicities and side effects via innovative dosing approaches, while maintaining the class-based wide anti-tumor efficacy. We look forward to continuing our work on these programs as we see great potential for treating multiple cancers.”
A link to the e-posters, listed below, is available through the AACR website.
Title: Novel, small molecule PRMT5 inhibitors for treatment of cancer
Poster Number: 1128
Date and Time: April 10, 2021 at 8:30 a.m. Eastern Daylight Time (EDT)
Session Title: Epigenetic Targets
Presenter: Dhanalakshmi Sivanandhan, et al.
Title: Novel, small molecule inhibitors of PD-L1/PD-1 interaction
Poster Number: 1630
Date and Time: April 10, 2021 at 8:30 a.m. Eastern Daylight Time (EDT)
Session Title: Immune Checkpoints
Presenter: Dhanalakshmi Sivanandhan, et al.
